Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Production of engineered dendritic cells and uses thereof

A technology of dendritic cells and precursor cells, applied in the direction of genetically modified cells, animal cells, vertebrate cells, etc., can solve the problems of mediating grafts, Treg instability, rejection, etc.

Pending Publication Date: 2021-04-02
フォンダツィオーネテレトン +2
View PDF14 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0013] - the possibility that infused Tregs are unstable under intense inflammatory conditions in vivo and adopt pathogenic effector T phenotypes and functions, thereby potentially mediating graft rejection;

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Production of engineered dendritic cells and uses thereof
  • Production of engineered dendritic cells and uses thereof
  • Production of engineered dendritic cells and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0451] LV-mediated gene transfer for transfer-specific Ag-derived peptides plus target sequences of miR155 and miR146a, known regulators of DC maturation (DC-Ag.miRNA), with IL-10 (DC-IL-10 / Ag) or IDO (DC-IDO / Ag), alternative strategies were developed to generate tolerogenic DC (tolLV DC) or ( figure 1 ). To determine the mode of action of tolLV-DC, the inventors used ovalbumin (OVA) as a model Ag. Generative encoding and OVA 315-353 fused Ii LVs containing OTII CD4 that can be transgenic by TCR + OVA recognized by T cells 323-339 , and this LV was used to transduce bone marrow (BM) cells during DC differentiation. LV.liOVA 315-353 .miR155T.miR146aT, LV.IL-10.IiOVA 315-353 , LV.IDO.IiOVA 315-353 , and the control LV.IiOVA 315-353 Used to obtain the following: DC-OVA, DC-OVA.miRNA, DC-IL-10 / OVA, DC-IDO / OVA. LV-DC is CD11c + and express CD80, CD86 and MHC class II at the same level as untransduced DC, ( figure 2 ). .DC-OVA promotes OTIICD4 + Proliferation of T cel...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure relates to a genetically modified dendritic cell or precursor thereof expressing at least one antigen-derived peptide and at least one immuno-modulatory molecule, its medical use and method of preparation. The invention also relates to an in vitro method to produce IL-10-producing CD49b+LAG-3+ Tr1 cells or antigen-specific FOXP3+ T cells and relative medical uses and pharmaceutical compositions.

Description

technical field [0001] The present disclosure relates to genetically modified dendritic cells or precursors thereof expressing at least one antigen-derived peptide and at least one immunomodulatory molecule, their medical uses and methods of making. The present invention also relates to the production of CD49b that produces IL-10 + LAG-3+Tr1 cells or antigen-specific FOXP3 + In vitro modalities of T cells, and related medical uses and pharmaceutical compositions. Background technique [0002] Identification of novel approaches aimed at selectively controlling antigen (Ag)-specific pathogenic T-cell responses and promoting / restoring tolerance in T-cell-mediated diseases represents an ambitious goal for the management of autoimmune diseases and organ transplantation in humans one. Consistent with this, a new type of vaccination (also known as "inverse vaccination" or "tolerogenic vaccination") aims to induce or restore an immune state in unresponsive situations, This may b...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12N5/0783C12N5/0784A61K35/15A61K35/17A61K39/00
CPCC12N2502/1121C12N2510/00C12N5/0637C12N5/064A61K38/00A61K39/39A61K39/0008A61P37/06A61P37/08A61K39/4622A61K39/464402A61K39/4621A61K39/4644A61K39/4637A61K39/4632A61K39/4615A61K2239/26A61K39/46434A61K35/15A61K45/06C12N15/85
Inventor A·安农尼S·A·格利高里
Owner フォンダツィオーネテレトン
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com